State University of New York, Brooklyn
Also known as: Department of Dermatology, State University of New York | DOWNSTATE CLINCL | Downstate Medical Center | Marina Boruk | Nand Wadhwa | New York Health Science Center | Stae University of New York Downstate Medical Center | Staten Island University Hospital | State University of New York Downstate | State University of New York - Downstate Medical Center | SUNY Downstate | SUNY Downstate Health Sciences University Department of Dermatology | SUNY Downstate Med Ctr | SUNY Downstate Medical | SUNY Downstate Medical Center Department of Anesthesiology | SUNY Downstate Medical Center, University Hospital of Brooklyn | SUNY Health Science Center, Brooklyn
Highest phase reached
Phase 4
First clinical trial
Aug 1, 1983First marketed drug
Aug 19, 1994First NDA
Aug 19, 1994Last known activity
Mar 14, 2025
Timeline
1860s
- Jan 1, 1860
State University of New York, Brooklyn— Founded
1990s
- Aug 19, 1994
fludeoxyglucose f-18— NDA Organization
- Aug 19, 1994
fludeoxyglucose f-18— NDA Secondary Org
Drugs by trial phase (54 distinct, 44 trials)
Phase 4 (11 own, 0 via acquisition)
Phase 3 (11 own, 0 via acquisition)
Phase 2 (22 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Other trials (6 own, 0 via acquisition)
Indications
Studied for
- Acne Vulgaris
- Anemia
- Anemia, Sickle Cell
- Apnea
- Asthma
- Autism Spectrum Disorder
- Autistic Disorder
- Child Development Disorders, Pervasive
- Disease
- Dysmenorrhea
- Dyspareunia
- Endometriosis
- Hematologic Diseases
- Hemoglobinopathies
- Hypertension
- Insulin Resistance
- Kidney Diseases
- Kidney Failure, Chronic
- Language Disorders
- Multiple Myeloma
- Nasal Polyps
- Neoplasms, Plasma Cell
- Panic Disorder
- Pneumonia
- Postoperative Pain
- Pruritus
- Psoriasis
- Renal Insufficiency, Chronic
- Retinopathy of Prematurity
- Rhinitis
- Rhinitis, Allergic
- Sleep Apnea, Obstructive
- Sleep Apnea Syndromes
- Syndrome
- Thalassemia
Marketed drugs (1)
Recent trials (50)
- NCT06952517OfficialPhase 2Mar 14, 2025
- NCT06940895OfficialPhase 2Mar 1, 2025
- NCT05977400CollaboratorPhase 3Apr 30, 2024
- NCT05796167Lead sponsorEarly Phase 1Jan 9, 2024
- NCT05796167Overall official - principal investigatorEarly Phase 1Jan 9, 2024
- NCT06030622Reponsible party - principal investigatorPhase 1/Phase 2Dec 1, 2023
- NCT06030622Sponsor investigatorPhase 1/Phase 2Dec 1, 2023
- NCT06030622Lead sponsorPhase 1/Phase 2Dec 1, 2023
- NCT04803227Overall official - principal investigatorPhase 1Mar 11, 2021
- NCT04755595Lead sponsorPhase 2Mar 9, 2021
- NCT04755595Reponsible party - principal investigatorPhase 2Mar 9, 2021
- NCT05439772Lead sponsorPhase 4Jan 1, 2021
- NCT05439772Reponsible party - principal investigatorPhase 4Jan 1, 2021
- NCT04369742CollaboratorPhase 2Apr 15, 2020
- NCT04289090Lead sponsorPhase 4Jan 14, 2020
Details
- Founded
- Brooklyn, NY, US Jan 1, 1860
- First NDA
- Aug 19, 1994
- Last known activity
- Mar 14, 2025
Designations held
- Priority review